Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study

Background: Checkpoint inhibitor immunotherapy or immuno-oncology (IO) treatment in refractory cervical cancer yielded an objective response rate (ORR) of 12% in tumors expressing the programmed cell death ligand-1 (PD-L1) in the KEYNOTE-158 phase II study. We hypothesized that the positive response...

Descripción completa

Detalles Bibliográficos
Autores principales: Shieh, Kevin R., Huang, Anna, Xu, Yiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387671/
https://www.ncbi.nlm.nih.gov/pubmed/34458284
http://dx.doi.org/10.3389/fmed.2021.669587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387671/
https://www.ncbi.nlm.nih.gov/pubmed/34458284
http://dx.doi.org/10.3389/fmed.2021.669587

Ejemplares similares